Significance of CD133 expression in esophageal squamous cell carcinoma

Table 3 Univariate survival analysis of clinicopathological findings and expression of molecular markers

	Variables	Number	Overall survival		Disease-free survival
			5-year overall survival rate (%)	P	5-year disease-free survival rate (%)	P
Age (years)	≤60	29	72.4	0.11	62.1	0.21
	>60	57	55.9	0.11	52.5	0.21
Sex	Male	73	58.7	0.13	51.9	0.080
	Female	13	76.9	0.13	76.9	0.080
Location	Cervix/upper	10	50.0	0.12	40.0	0.067
	Middle/lower	76	63.0	0.12	57.8	0.067
Histological type	Well or moderate	73	61.5	0.64	57.4	0.36
	Poor	13	61.5	0.64	46.2	0.36
pT	pT1/pT2	37	78.1	0.0012	70.0	0.0033
	pT3/pT4	49	49.0	0.0012	44.9	0.0033
pN	pN0	36	80.6	0.0051	75.0	0.0078
	pN1-3	50	47.7	0.0051	41.7	0.0078
pStage	pStageI/II	48	79.0	0.0002	72.8	0.0002
	pStageIII/VI	38	39.5	0.0002	34.2	0.0002
Lymphatic invasion	Negative	34	70.2	0.086	58.4	0.29
	Positive	52	55.8	0.086	53.9	0.29
Venous invasion	Negative	31	64.5	0.47	54.8	0.63
	Positive	55	59.8	0.47	56.2	0.63
p53	Negative	29	62.1	0.30	55.2	0.55
	Positive	57	61.3	0.30	56.1	0.55
p16	Negative	69	58.0	0.19	53.6	0.14
	Positive	17	76.0	0.19	63.7	0.14
p27	Negative	37	56.8	0.30	54.0	0.49
	Positive	49	65.0	0.30	56.9	0.49
MDM2	Negative	66	63.6	0.31	59.1	0.61
	Positive	20	53.3	0.31	59.2	0.61
Ki-67	<30	43	69.8	0.24	62.8	0.27
	≥30	43	53.2	0.24	48.6	0.27
EGFR	Negative	46	69.6	0.22	63.0	0.16
	Positive	40	52.0	0.22	47.1	0.16
CD133	Negative	48	54.2	0.049	47.9	0.059
	Positive	38	70.8		65.5

ISSN: 1477-7819